The company completed a clinical trial at nine centers across the U.S., Europe and Asia before it received FDA approval.

New research shows that inhibiting overactive LRRK2 enzymes could stabilize Parkinson's disease progression, with Stanford ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to ...

Insightec, a global healthcare innovator dedicated to using focused ultrasound to transform patient care, announced today that the U.S. Food and Drug Administration (FDA) has approved the use of its ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

In its last fund raising round last year, Insightec’s valuation was at just $515 million, as emerges from the financials of listed company Elbit Medical, which holds 2% of Insightec.

An active ingredient in cough medicines since 1979 has shown promise as a treatment for neuropsychiatric symptoms in ...

Parkinson's disease is a neurogenerative disease that affects more than 1 million people in the U.S. While some cases are ...

DelveInsight's Parkinson's Disease Pipeline report depicts a robust space with 130+ active players working to develop 150+ ...

Epworth Geelong has become the first hospital outside Melbourne to offer deep brain stimulation, giving Western Victorians with Parkinson's disease ...

The drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...

Groundbreaking research by Sydney University found a new brain protein involved in Parkinson’s disease and a way to modify it ...